Orna Therapeutics Enhances Circular RNA Capabilities, Acquires ReNAgade Therapeutics

Image Credit: Adobe Stock Images/NateeMeepian.com Orna Therapeutics, a biotechnology company that strives to design new classes of fully engineered circular RNA therapeutics (oRNA), has acquired ReNAgade Therapeutics.1 The company’s goal is to a “unlock the potential of RNA therapeutics,” specifically pertaining to delivery that demonstrated to multiple extra-hepatic cells in non-human primate (NHP) models over […]

Continue Reading

Biogen Agrees to Acquire HI-BIO for $1.15 Billion

Image Credit: Adobe Stock Images/ColorCrafts.com Biogen Inc. and Human Immunology Biosciences (HI-Bio), a clinical-stage biotech company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), have entered into a definitive agreement under which Biogen will be purchasing HI-Bio for $1.15 billion upfront and up to $650 million in possible milestone payments. As of now, […]

Continue Reading

TFF Pharmaceuticals, Cleveland Clinic to Move Their Influenza Vaccine Candidates into Preclinical Testing

Image Credit: Adobe Stock Images/LeighPrather.com Alongside Cleveland Clinic, TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, will be advancing numerous multivalent universal influenza vaccines into preclinical testing.1 These vaccines reportedly protect against seasonal and pandemic viruses; the choice to send these candidates through into preclinical testing was based on the completion of formulation testing with stability […]

Continue Reading

Tower Cold Chain Submits Its First-Ever Sustainability Report

Image Credit: Tower Cold Chain Tower Cold Chain, who was recently interviewed by Pharmaceutical Commerce at LogiPharma Europe,1 has published its first Sustainability Report,2 which outines the company’s pledge to following environmental, social and governance (ESG) principles. The report also lays out the environmental benefits that come with using its passive temperature-controlled containers for the […]

Continue Reading

Astellas, YASKAWA Sign Cell Therapy MoU Powered by Robotics Technology

Image Credit: Adobe Stock Images/Funtap.com Astellas Pharma has signed a memorandum of understanding (MoU) with YASKAWA Electric Corporation, signifying early talks to design a cell therapy ecosystem with the use of pharmaceutical and robotics technology.1 Although this particular memorandum is legally non-binding and technically not required to be followed, both parties expect that it will […]

Continue Reading

Johnson & Johnson Purchases Proteologix for $850 Million

Image Credit: Adobe Stock Images/Lial88.com In an $850 million deal, Johnson & Johnson will be acquiring Proteologix, Inc., a privately-held biotech company that specializes in bispecific antibodies for immune-mediated diseases.1 There is also the opportunity for an additional milestone payment. The Proteologix portfolio features PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in […]

Continue Reading

AstraZeneca to Build $1.5 Billion Antibody Drug Conjugates Manufacturing Plant in Singapore

Image Credit: Adobe Stock Images/Huenstructurebio.com AstraZeneca will be constructing a $1.5 billion manufacturing facility1 in Singapore for antibody drug conjugates (ADCs)—treatments that provide cancer-killing agents directly to cancer cells through via targeted antibody—which will further boost its current ADC portfolio. Design and construction are expected to begin by the end of this year, with full […]

Continue Reading

Cold Chain Solutions Supplement: Further Exploration of Pharma’s Temperature-Controlled Sector

Post LogiPharma, the editors of Pharmaceutical Commerce examine the trends and highlights that came out of the conference, specifically surrounding the cold chain solutions segment. This digital supplement offers an overview of this niche sector’s value to the industry, and through exclusive video interviews with key opinion leaders and session coverage, provides perspectives from subject […]

Continue Reading